Notably, no difference in lifespan was observed between the untreated and IDA-treated subgroups (Fig. 3C and Supplementary Fig. S5G), indicating that the therapeutic effect of IDA was blocked by the overexpression of METTL3 and strongly suggesting that METTL3 played a significant role in enhancing AML chemoresistance in the long term. Here, METTL3 is linked to acute myeloid leukemia.